Cantor Fitzgerald Reiterates a Buy Rating on Radius HealthBy Carrie Williams
“Waiting on a Partner. Radius has maintained expectations to have a commercial partner in place in Europe for the abaloparatide-SC by launch, and has become a focal point for investors, in our view. This plan was reiterated on the company’s EPS call, though we think the long time horizon to an announcement has been viewed as a disappointment. Nonetheless, as European is anticipated by early 2017 followed by U.S. approval, a partner may not be too far off.”
According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -6.0% and a 33.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Axsome Therapeutics Inc.
Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $71.
The company has a one year high of $75.50 and a one year low of $24.75. Currently, Radius Health has an average volume of 1.15M.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.
Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women’s health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.